Question of the Day

Question of the Day – Monday July 24, 2017

Question:  Occupational exposure to the chemical carbon disulfide has been associated with a wide variety of adverse health effects including accelerated atherosclerosis in some workers. What phenomena have been posited as surrogate markers for the absorption of a medically important dose of carbon disulfide?

View full post for answer.

Question of the Day – Friday July 21, 2017

Question: Eculizumab (Soliris) is licensed in the United States for treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; both are rare, life-threatening illnesses. An increased risk for which infectious disease is associated with the use of Eculizumab?

View full post for answer.

Question of the Day – July 10, 2017

Question:  The combination of 5-hydroxytryptamine (5-HT3) receptor antagonist and dexamethasone is often recommended for the treatment of vomiting related to cancer chemotherapy. What other common complication occurs in this setting and is most often due to dexamethasone?

View full post for answer.